AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through
HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced...
A chronographic analysis of MSC's rollercoasting journey
TIANJIN, China, March 18, 2025 /PRNewswire/ -- On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking...
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1...